Figures cited from the PR Newswire release “Nanochon Performs First Case in the Chondrograft™ First in Human Clinical Study” (2 September 2026, 16:58 ET), the live ClinicalTrials.gov record NCT07542184 (last update posted 21 August 2026; first posted 21 April 2026), and published bioaccess® Panama pages, verified 3 September 2026. General information, not legal or regulatory advice. Confirm current MINSA, CNBI, and FDA rules with qualified advisers. We name only the investigators, facility, and trial those sources support, and we do not reprint site contact emails or phone numbers. Nanochon is not claimed as a bioaccess® client. bioaccess® is not listed on this NCT and did not run this study.
If you searched Dr. Juan Osorio Panamá, Juan Osorio principal investigator Chondrograft, Emilio Tufiño knee cartilage trial, Nanochon first case Panamá, or “go direct to the surgeon,” you followed an investigator string that public press and ClinicalTrials.gov both publish. Dr. Juan Osorio is a real named principal investigator. He is not the operator of the MINSA file.
bioaccess®’s position is simple and it is not adversarial: the investigator is the investigator and the hospital is the site. The First-in-Human CRO still owns MINSA / CNBI, investigational import, insurance, ISO 14155 monitoring, and the FDA 21 CFR 812.28 package — plus the option to add Colombia or another Latin American country if Panamá is not the only fit. Sponsors who skip the CRO and email the surgeon still have to rebuild that stack. A principal-investigator line does not become a CRO.
This is a person-string intercept, and it exists only because the building already has its own page. The facility intercept stays at The Panama Clinic (Spanish: versión en español), and the distinct legal-entity string stays at CEVAXIN / The Panama Clinic. This page does not clone clinical trials in Panama. That page stays the country operating system.
Why the surgeon’s name wins the search — and why that is not a CRO
On 2 September 2026, Nanochon announced the successful treatment of the first patient in its First-in-Human study of Chondrograft™, a 3D-printed implant for articular cartilage defects of the knee. Per that release: Dr. Juan Osorio and Dr. Emilio Tufiño, both specialists in regenerative sports medicine, performed the first procedure at The Panama Clinic, Panamá. Dr. Osorio is quoted in the release identifying himself as the Principal Investigator for the study. Dr. Tufiño is quoted describing the procedure as “bone-sparing, minimally invasive, and streamlined.” The release also states that Nanochon plans a Level 1 multi-center, randomized, controlled pivotal trial after the FIH study, and that Chondrograft™ has FDA Breakthrough Device Designation. No CRO is named anywhere in that release.
The registry says the same thing in registry language. NCT07542184 — brief title: Nanochon Chondrograft First in Human (FIH) Early Feasibility Study (EFS) – Panama. Official title: A First in Human (FIH) Early Feasibility Study (EFS) to Evaluate the Safety and Performance of the Nanochon Chondrograft™ Implant for Re-surfacing of Cartilage Lesions. Organization study ID: 101-2024 – PAN. Lead sponsor: Nanochon, Inc., class INDUSTRY, responsible party the sponsor. No collaborator is listed. No CRO is listed.
Design on the 3 September 2026 snapshot: interventional; single-group; no masking; primary purpose treatment; phase N/A; estimated enrollment 5. Actual start 30 July 2026; estimated primary completion and completion September 2027. Study first posted 21 April 2026; last update posted 21 August 2026 — that is, before the 2 September first-case announcement. Status RECRUITING. Condition: knee cartilage lesions, with registry keywords for medial and lateral femoral condyle and trochlear articular cartilage lesions. Intervention: a device — mini-arthrotomy or arthroscopic surgical implantation of the Nanochon Chondrograft. Eligibility: male or female aged 22–60, MRI knee evaluation within six months, able to read and speak English and/or Spanish, and voluntary signature of the REB-approved informed consent.
The single Panama location row is The Panama Clinic, Panama City, Provincia de Panamá, RECRUITING, with Juan Osorio, MD listed as PRINCIPAL_INVESTIGATOR. That is the registry’s own field, not our inference. A sister Canadian record, NCT07249489 (same official title, org study ID 101-2024-CAN, estimated n=10, NOT_YET_RECRUITING, last update posted 2 September 2026), lists University of British Columbia in Vancouver and an Orthopaedic Clinic in Toronto. Canada is outside the Latin American geography this page covers; we note it so nobody merges the two records.
Read the two sources together. An estimated five patients, a 3D-printed implant, a Breakthrough-designated device, a planned pivotal RCT to follow — and the only human names a sponsor can find are two surgeons and a company CEO. That is the site-direct leak in its purest form: the search resolves to a person, and the person is not the operator of the file.
The investigator is the investigator. The CRO is the operator.
A regenerative sports-medicine surgeon in Panama City can carry the procedure, the surgical judgement, the follow-up exams, and the source documents. That is necessary, and on this program it is clearly working — the first case was enrolled and treated quickly enough that the sponsor made a point of it. It is still not the same job as owning a first-in-human file.
What a named investigator and their hospital can typically do when a sponsor “goes direct”:
- Discuss investigator interest and surgical feasibility for a cartilage protocol — when that service is available and appropriate for your device, which is not automatic.
- Share institutional ethics-committee calendars and hospital research rules.
- Quote procedure, theatre, and local staffing costs for the cases they will physically perform.
What an investigator is not built to own for an investigational device:
- MINSA and the CNBI. The national file and the national bioethics pathway are not a hallway conversation with a surgeon.
- Investigational import. Ethics letter, investigator’s brochure, and an importation permit, end to end. See importer of record for clinical trial devices in Latin America.
- Clinical trial insurance. Required. The published bioaccess® Panama planning band is $5,000–$15,000 depending on device risk and enrollment. That is a published planning band, not a quote for this study.
- ISO 14155 monitoring, EDC, adverse-event reporting, and the TMF — across Panamá and any second country.
- The 21 CFR 812.28 package. Foreign data is eligible for FDA submission and review after the GCP and ethics documentation that rule defines. Eligibility is not clearance. See OUS FIH and FDA IDE.
- Multi-country optionality. A five-patient EFS that is meant to feed a Level 1 pivotal trial is exactly when one surgeon’s calendar stops being the plan.
Going direct to Dr. Osorio is how you confirm a surgeon. It is not how you open an investigational file.
Investigator versus CRO
| Workstream | What the named investigator and hospital typically own | What the CRO still owns |
|---|---|---|
| Procedure | Mini-arthrotomy or arthroscopic implantation, imaging, follow-up exams | Protocol fit, training, implant accountability |
| Ethics | Institutional committee calendar and local rules | Packet, ICF, IB alignment, deficiency cycle |
| National authority | Not the permit holder by being named as PI | MINSA / CNBI file |
| Import | Receiving and storage if contracted | Importer of record for the investigational implant |
| Quality | Source documents from the cases performed | ISO 14155 monitoring, EDC, AE reporting, TMF |
| FDA conversation | Clinical judgement and case data | 21 CFR 812.28 narrative — eligibility, not clearance |
| Scale-up | One surgical team in Panama City | Second country, pivotal readiness, Colombia (INVIMA) and the rest of the platform |
What the Nanochon public file actually supports — and what it does not
- Device: Chondrograft™, a 3D-printed implant for focal articular cartilage defects of the knee, with FDA Breakthrough Device Designation per the company release.
- Sponsor: Nanochon, Inc. (industry). No collaborator on the NCT. No CRO named in the release or on the record.
- Site: The Panama Clinic, Panama City — the only Panama location row, RECRUITING. Already intercepted on its own page.
- Named investigators (as published): Juan Osorio, MD — principal investigator on the NCT row and self-identified as PI in the 2 September release; Emilio Tufiño, MD — named in the release as performing the first procedure. We do not merge them into a single identity and we do not add a third name.
- Milestone: first patient treated, announced 2 September 2026. Actual study start on the registry is 30 July 2026.
- Not claimed here: that bioaccess® ran this study or is on this NCT; that Nanochon is a bioaccess® client; that we have Chondrograft outcomes; that Breakthrough Device Designation is clearance or approval; that the Panama and Canada records are one study.
What the CRO still does after you have a surgeon’s name
- Regulatory-fit, not tourism. Panamá is a lead first-in-human jurisdiction on the published platform. It is not automatically the right country for every indication. bioaccess® still runs clinical trials in Colombia and the rest of the platform.
- Protocol, IB, ICF, insurance, and the MINSA / CNBI packet.
- Importer of record and implant accountability.
- ISO 14155 monitoring and the 21 CFR 812.28 narrative for the FDA conversation that a Breakthrough-designated implant will eventually need.
- Optionality when a five-patient EFS has to become a multi-centre pivotal study.
The founder podcast, when a conversation needs a voice, is Global Trial Accelerators™. Background: LATAM FIH hospitals vs the CRO.
Frequently asked questions
Why is there a page for a person rather than only for the hospital?
Because sponsors search the string they see, and the 2 September release put two surgeons’ names in front of the building. The facility page already exists at The Panama Clinic, and the legal-entity page exists at CEVAXIN. This page answers the investigator query and links back rather than duplicating either one.
Can I contract Dr. Osorio directly?
You can try. A principal investigator can discuss surgical feasibility, institutional ethics calendars, and local case costs. He cannot become your MINSA applicant, importer of record, insurer, ISO 14155 monitor, or 21 CFR 812.28 packager because a press release named him. Contract the CRO; let the CRO activate the site and the investigator.
Did bioaccess® run the Chondrograft first-in-human study?
No. No public bioaccess® page says so, bioaccess® is not on NCT07542184, and we will not invent that relationship. This page intercepts the search; it does not claim the study.
Does Breakthrough Device Designation mean the implant is approved?
No. The company release states the designation; a designation is a review-interaction pathway, not clearance or approval. A first-in-human EFS is still an investigational study, and foreign data still has to meet 21 CFR 812.28 conditions to be eligible for FDA submission and review.
Is Colombia still an option?
Yes. bioaccess® still runs trials in Colombia. A Panamá investigator search is not an instruction to abandon INVIMA. See CRO in Colombia.
Leave a Reply